Arthritis

Latest

FDA Approves Knee OA Treatment for 26 Weeks

FDA Approves Knee OA Treatment for 26 Weeks

The FDA has approved 26-week treatment efficacy claims for Zimmer Biomet's knee osteoarthritis product.

Can Tocilizumab Treat RA After Non-TNFi Failure?

Can Tocilizumab Treat RA After Non-TNFi Failure?

Better efficacy for tocilizumab versus abatacept and rituximab in patients with first non-TNFi failure.

Vitamin D May Not Benefit Knee Osteoarthritis

Vitamin D May Not Benefit Knee Osteoarthritis

Supplements didn't slow disease progression or ease pain, even in patients with low levels of vitamin D.

What is the Most Effective NSAID to Relieve Knee OA Pain?

What is the Most Effective NSAID to Relieve Knee OA Pain?

A team of researchers from Switzerland studied the efficacy of different formulations and doses of NSAIDs on osteoarthritis pain by conducting a network meta-analysis.

Can Obese Patients With Knee Osteoarthritis Benefit From A New Home-Based Device?

Can Obese Patients With Knee Osteoarthritis Benefit From A New Home-Based Device?

Biomechanical device tied to improvement in all gait parameters at three, 12 months.

Arthritis Patients: We Want Info About Multiple Drug Options

Arthritis Patients: We Want Info About Multiple Drug Options

Patients with inflammatory arthritis want to be informed about current, future treatment options.

Rituximab Retreatment At Clinical Relapse Cost-Effective In RA

Rituximab Retreatment At Clinical Relapse Cost-Effective In RA

At least as cost-effective as more intensive regimen in patients with longstanding RA.

RA Not Linked With Increased Carpal Tunnel Incidence

RA Not Linked With Increased Carpal Tunnel Incidence

Incidence rate 4.18 per 1,000 person-years; similar to incidence in the general population.

New Data on Baricitinib for RA From Phase 3 Trial

New Data on Baricitinib for RA From Phase 3 Trial

Eli Lilly and Company and Incyte announced results from a second Phase 3 trial with baricitinib in patients with rheumatoid arthritis.

Scores Underidentifying RA Patients With CVD Risk

Scores Underidentifying RA Patients With CVD Risk

Ten-year risk score yielded no better results than Framingham Risk Score, Reynolds Risk Score, according to the researchers.